Successful conversion therapy for unresectable hepatocellular carcinoma is getting closer: A systematic review and meta-analysis
BackgroundConversion therapy provides selected patients with unresectable hepatocellular carcinoma the opportunity to undergo a curative hepatectomy and achieve long-term survival. Although various regimens have been used for conversion therapy, their conversion rate and safety remain uncertain. The...
Main Authors: | Yinxuan Pei, Weiwei Li, Zixiang Wang, Jinlong Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.978823/full |
Similar Items
-
Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors
by: Xingzhi Li, et al.
Published: (2023-01-01) -
The safety and efficacy of TACE combined with HAIC, PD-1 inhibitors, and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a retrospective study
by: Zhongjing Huang, et al.
Published: (2024-01-01) -
Transarterial Chemoembolization in Hepatocellular Carcinoma, Albanian Experience.
by: Ilirian Laçi, et al.
Published: (2022-07-01) -
Longer Survival and Preserved Liver Function after Proton Beam Therapy for Patients with Unresectable Hepatocellular Carcinoma
by: Takuto Nosaka, et al.
Published: (2023-03-01) -
Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
by: Yu B, et al.
Published: (2023-10-01)